Patent 7709538 Issued on May 4, 2010. Estimated Expiration Date: July 14, 2028. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
The present invention relates to a method of treating a non-tumor condition or disease associated with angiogenesis in a human or animal comprises administering thereto an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges in a pharmaceutically acceptable carrier.
Felix Bock Ph.D. et al., Corneal (Lymph)angiogenesis—From Bedside to Bench and Back: A Tribute to Judah Folkman, Lymphatic Research and Biology, 2008, 191-201, vol. 6, No. 3-4.
M. Murata M.D., Ph.D. et al., The potential role of vascular endothelial growth factor (VEGF) in cartilage How the angiogenic factor could be involved in the pathogenesis of osteoarthritis?, Osteoarthritis and Cartilage, 2008, pp. 279-286, vol. 16.
Gaelle Clavel et al., Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction, Clinical Immunology, 2007, 158-164, vol. 124.
Pedro R. Moreno et al., Neovascularization in Human Atherosclerosis, Circulation, 2006, 2245-2252, vol. 113.
Jan S.A.G. Schouten et al., A systematic review on the effect of bevacizumab in exudative age-related macular degeneration, Graefes Arch Clin Exp Ophthalmol, 2009,1-11, vol. 247.
Richard F. Spaide et al., Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion, Am J Ophthalmol, 2009, 298-306, vol. 147, Elsevier Inc.
Ashley J. Duits et al., Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease, British Journal of Haematology, 2006, 116-119, 134, Blackwell Publishing Ltd.
Thomas A. Ciulla et al., Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration, Current Opinion in Ophthalmology, 2009, pp. 166-174, vol. 20.
Gupta et al. Postgrad. Med. J., 2005, vol. 81, pp. 236-242.
Pandya et al. Vascular Pharmacology, 2006, vol. 44, pp. 265-274.